r.rotation.to⌕ Search stocks, people, sectors
Request a free account

Follow the people · Insider

JH

Jason Haas

Insider · Director · LGND

Jason Haas files insider transactions with the SEC as a director of Ligand Pharmaceuticals (LGND). We hold 3 disclosed purchases and sales filed since 13 October 2021, 2 of them in the last 90 days.

  • Files forLGND
  • Disclosed buys and sells3 in all, 2 in the last 90 days
  • Last disclosure14 August 2026

Positions held

3 posts we hold — a term names its own dates; a run of filings only says when they filed
  • Filed 29 June 2022 — 12 August 2026Director · Ligand Pharmaceuticals (LGND)19 Form 4 lines · source: SEC Form 4
  • Filed 8 May 2026 — 8 May 2026Chief Financial Officer · Odyssey Therapeutics (ODTX)1 Form 4 line · source: SEC Form 4
  • Filed 12 October 2021 — 18 November 2024Chief Financial Officer · Syros Pharmaceuticals (SYRS)24 Form 4 lines · source: SEC Form 4

Everything they disclosed

44 entries, newest first — one per disclosure report, one per Form 4 line

Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.